Compounded Tirzepatide
A non-FDA-approved compounded tirzepatide; legal only while Mounjaro/Zepbound remain on the FDA shortage list. Costs $150-$400/month versus $1,000+ for
Compounded tirzepatide became widely marketed during the Mounjaro/Zepbound shortage period. Its legal availability hinges on whether the FDA lists tirzepatide as in shortage; once removed, traditional compounding under the 503A pathway is significantly restricted. Patients should confirm their compounded preparation comes from a state-licensed pharmacy and ask about sterility, potency testing, and excipients.